GlassScriptPhysician profile
Evan M Davidson
NPI 1902245848
$2,090.31
in general payments reported to CMS, 2019-2025
31 companies · $316 in 2025
The $316 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $649 · 2020: $269 · 2021: $12.61 · 2022: $159 · 2023: $246 · 2024: $439 · 2025: $316.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,001.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,001.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $329.16 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $257.26 | 2019-2024 | Onureg, Opdivo |
| Gilead Sciences, INC. | $244.74 | 2020-2025 | Trodelvy |
| Novo Nordisk INC | $176.21 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $146.58 | 2019-2024 | Spravato |
| Astellas Pharma US INC | $100.79 | 2019-2025 | Cresemba |
| Abbvie INC. | $95.38 | 2019-2024 | |
| Daiichi Sankyo INC. | $88.62 | 2022-2025 | Enhertu, Injectafer |
| Boehringer Ingelheim Pharmaceuticals, INC. | $81.18 | 2019-2023 | |
| Kite Pharma, INC. | $63.89 | 2025 | Yescarta |
| Tempus Ai, INC | $44.90 | 2024-2025 | Xt Cdx |
| Array Biopharma INC | $39.50 | 2023-2025 | Braftovi, Lorbrena, Mektovi |
| Genzyme Corporation | $35.93 | 2023 | |
| Aveo Pharmaceuticals, INC. | $34.69 | 2022-2025 | |
| Myriad Genetic Laboratories, INC. | $32.99 | 2024 | Myrisk |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $32.73 | 2025 | |
| Servier Pharmaceuticals LLC | $26.19 | 2025 | |
| Amarin Pharma, INC. | $24.95 | 2020 | |
| Tersera Therapeutics LLC | $24.58 | 2024 | Xermelo |
| Genmab U.S., INC. | $24.01 | 2024 | Epkinly |
| Glaxosmithkline, LLC. | $21.50 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.91 | 2025 | |
| Agios Pharmaceuticals, INC. | $19.53 | 2025 | Pyrukynd |
| Allergan, INC. | $19.39 | 2020 | |
| Pfizer INC. | $18.81 | 2023 | |
| Ipsen Biopharmaceuticals, INC | $16.22 | 2022 | |
| Celltrion USA INC. | $16.14 | 2025 | Vegzelma |
| Sanofi-Aventis U.S. LLC | $15.30 | 2019 | |
| Pharmacosmos Therapeutics INC. | $15.24 | 2023 | Monoferric |
| Lilly USA, LLC | $12.38 | 2019 | |
| Radius Health, INC. | $11.61 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Evan Davidson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.